PALM BEACH, Florida, June 4, 2020/ PRNewswire/– According to an short article by the National Cannabis Industry Association, Nanoemulsions will have an effect in the medical, beverage and instilled markets in the coming months and years. Customers and producers of items that have actually been instilled with THC or CBD are most likely very knowledgeable about 2 crucial problems that plague the item class: sluggish onset time and irregular dosing of the active component. In a quote to provide a service, numerous groups are marketing “water-soluble innovation,” or “nanotechnology.” The vast bulk of the groups declaring water-soluble (more correctly referred to as “water-compatible”) technology are providing a nanoemulsion. Nanoemulsion technology is a very promising and available option. It has the ability to permit both (1) fast start and (2) consistent distribution of the active component in infused products such as beverages, gummies, and water-based topicals. When made small enough, the particles disperse uniformly in water and will not separate out into bigger globs of oil. Other added benefits are increased absorption of the active ingredient. Active business in the markets today consist of: Pressure BioSciences, Inc.(OTCQB: PBIO), Canopy Development Corporation ( NYSE: CGC) (TSX: WEED), HEXO Corp. ( NYSE: HEXO) (TSX: HEXO), Cronos Group Inc. ( NASDAQ: CRON) (TSX: CRON), ycbdMD, Inc. ( NYSE: YCBD).
Another research study by Coherent Marketing Insights added: “There are a number of advantages of nanoemulsion over standard emulsion. One such advantage is the severe micro-droplet size of nanoemulsion with high surface location, which makes them highly reliable as a transport system.
Pressure BioSciences, Inc (OTCQB: PBIO) BREAKING NEWS: Pressure BioSciences Announces First Manufacturing Build Entirely Sold Out for Revolutionary UST System for Processing Hemp-Derived Cannabinoid Oil into Steady, Water-Soluble Nanoemulsions – Pressure BioSciences today revealed the receipt of an order for the 12 th and last system set up to be built in the Company’s preliminary manufacturing run of its advanced BaroShear ™ K45 processing system. Based on the Business’s exclusive Ultra Shear Technology ™ (UST ™) platform, the BaroShear K45 is a special and powerful nanoemulsification system developed to deal with one of the most vital issues facing the global hemp-derived cannabinoid industry today: how to make hemp-derived cannabinoid oil successfully soluble in water, to optimize absorption and bioavailability when taken in or used. The cannabidiol market is forecasted to go beyond $20 B by 2024 ( Forbes, Might 2019).
Hemp-derived cannabinoids are drawn out from the hemp plant in an oil. Similar to any oil-based product, it is hard for the water-based biology of our human bodies to gain access to and soak up the tiny hemp-derived cannabinoid particles that are concealed within hemp oil drops. These drops stay relatively large after standard aggressive emulsification methods, which leads to poor and variable absorption levels of hemp-derived cannabinoid molecules in the body for the treatment of targeted conditions. Low or widely varying levels of hemp-derived cannabinoid absorption and biological ease of access is a vital issue that may significantly affect the bioavailability and effectiveness of the possible advantages of hemp-derived cannabinoid items on the market today.
The Business previously revealed plans for its first production run of twelve (12) BaroShear K45 processing systems with approximated completion times throughout the fourth quarter of2020 Due to ineffectiveness brought on by the COVID-19 pandemic, the Business now believes that all 12 systems will be completed in time for shipment and setup to happen throughout the very first quarter of 2021.
Mr. Kenneth F. Micciche, Director of PBI’s UST Program, said: “The order for the last available BaroShear K45 system from our initial production run was gotten from an exciting young business out of Massachusetts called Canopy CBD Farms, LLC. They use only the greatest quality hemp biomass available and the most current processing innovations to fulfill or go beyond industry requirements.
Mr. John Westlake, Founder and President of Canopy CBD Farms, LLC., commented: “Scientific information strongly supports the important understanding that hemp-derived cannabinoid oil requires to be processed into an effectively water-soluble, long-term stable nanoemulsion to attain the greatest quality hemp-derived cannabinoid products possible.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We are very gratified and excited that the initial manufacturing run of our BaroShear K45 processing systems has actually sold out. We are also pleased that a remarkable, up-and-coming company like Canopy CBD Farms had the ability to take part in and position an order for the last available unit in our very first manufacturing run. We are confident that the BaroShear K45 will differentiate them in the market with a considerable benefit over their competitors.” Read this and more news for Pressure BioSciences at: https://www.financialnewsmedia.com/news-pbio/
Other recent developments in the markets include:
Canopy Growth Corporation ( NYSE: CGC) (TSX: WEED.TO) has just recently offered updates on the Company’s 2.0 innovation products that have actually launched into the Canadian recreational market in early 2020, and extra upcoming product releases.
The very first wave of the Business’s ready-to-drink cannabis-infused beverages — Tweed Houndstooth & Soda and Tweed Bakerstreet & Ginger — shipped in March 2020 and April 2020, respectively. Houndstooth & Soda– the very first THC instilled ready-to-drink beverage to strike the Canadian market– amassed positive early evaluations and strong customer need throughout the nation, with additional deliveries having given that been sent out to provincial boards and retailers to meet continuous demand. Canadians can anticipate to see 2 additional drinks– Houseplant Grapefruit and Deep Space — readily available through retail and e-commerce platforms within the coming weeks.
A year back, the Company updated its medical product packaging to comply with the Cannabis Laws, resulting in smaller product formats.
” We know our medical clients have actually been waiting on this chance to buy a higher volume of marijuana without excess packaging,” said HEXO CEO and co-founder Sebastien St-Louis “Our Tsunami flower take advantage of improved humidity controls for maximum freshness and to promote ideal bud density.”
Cronos Group Inc. ( NASDAQ: CRON) (TSX: CRON.TO) just recently released its 2020 very first quarter company results. “Cronos Group began 2020 stimulated and determined to continue to translucent our core tactical efforts to drive long-lasting and sustainable development. This quarter, we moved better to formally going into the Israeli medical marijuana market with our Cronos Israel operations preparing to offer PEACE NATURALS ™ branded dried flower products to medical patients. The Israeli medical market is a growing channel, and we look forward to serving this market in 2020 and beyond,” stated Mike Gorenstein, CEO of Cronos Group.
” Despite the challenges and unpredictability posed by the COVID-19 pandemic, we stay nimble and focused as a business. Our brand name portfolio continues to release ingenious products to consumers as we adjust to an online-first distribution design in both the U.S. and Canada We continue to reach our stakeholders and consumers through imaginative digital marketing. And our product innovation and R&D tasks continue to advance. Our company believe the objective of our Company, to improve lives through cannabinoid innovation, resonates particularly well throughout these times. We stay well-positioned and devoted to producing sustainable, long-term worth for investors and are positive 2020 will be a successful structure year for Cronos Group.”
cbdMD, Inc. ( NYSE: YCBD) just recently reported its second financial 2020 quarter ended March 31, 2020 results. “We are pleased to report strong 2nd quarter results, in addition to offer a mid-quarter upgrade on operations. We reported $ 9.4 million in quarterly net sales, a 67%boost over the exact same quarter in 2015. Our gross revenue margin stays strong at 67%year-to-date and 70.9%for the quarter. Our general direct to consumer e-commerce sales for the March financial quarter were $ 6.8 million or 72%of our total net sales, an increase of $ 2.5 million or 58%from the prior year’s quarter. Our B2B physical sales were $ 2.6 million or 28%of our overall net sales, a boost of $ 1.2 million or 85%from the previous year’s quarter. Direct to customer e-commerce sales for the six months ending March were $136 million or 70%of our total net sales, an increase of $ 8.9 million or 189%from the prior year duration. Our B2B traditional sales were $ 5.9 million or 30%of total net sales, an increase of $ 4.5 million or 321%from the prior year period. Our operating costs for the March quarter were $122 million, of which around $665,000 was non-cash expenses, leading to a money usage of $ 4.2 million for the quarter. Year to date our operating costs were $248 million, of which approximately $ 1.5 million was non-cash costs, resulting in a cash use of around $ 9.1 million for the six months ending March 31, 2020,” said Martin Sumichrast, Chairman and co-CEO of the Business.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which distributes electronic details through several online media channels. FNM is NOT connected in any way with any business discussed herein. FNM and its affiliated business are a news dissemination options provider and are NOT a registered broker/dealer/analyst/ consultant, holds no financial investment licenses and may NOT sell, offer to offer or provide to purchase any security. FNM’s market updates, news informs and business profiles are NOT a solicitation or suggestion to purchase, offer or hold securities. The product in this release is planned to be strictly educational and is NEVER to be construed or analyzed as research study material. All readers are strongly advised to carry out research study and due diligence by themselves and seek advice from a licensed financial professional prior to considering any level of purchasing stocks. All product consisted of herein is republished content and details which were formerly shared by the business pointed out in this release. FNM is not responsible for any investment choices by its readers or subscribers. Financiers are cautioned that they might lose all or a portion of their financial investment when purchasing stocks. For existing services performed FNM has been compensated forty 6 hundred dollars for news protection of the present news release provided by Pressure BioSciences, Inc. by the Company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “positive declarations” within the meaning of Section 27 A of the Securities Act of 1933, as modified, and Section 21 E the Securities Exchange Act of 1934, as modified and such forward-looking declarations are made pursuant to the safe harbor arrangements of the Personal Securities Litigation Reform Act of1995 You are warned that such declarations are subject to a plethora of dangers and uncertainties that might cause future scenarios, events, or results to vary materially from those predicted in the forward-looking statements, consisting of the dangers that actual results may vary materially from those forecasted in the forward-looking statements as a result of numerous factors, and other threats identified in a company’s yearly report on Form 10- K or 10- KSB and other filings made by such business with the Securities and Exchange Commission.
Media Contact e-mail: [email protected]